Edition:
United Kingdom

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

3.51USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$3.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
71,103
52-wk High
$30.60
52-wk Low
$2.72

Latest Key Developments (Source: Significant Developments)

Advaxis Announces Pricing Of Its Public Offering Of Common Stock
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF COMMON STOCK.ADVAXIS ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF COMMON STOCK.ADVAXIS INC - OFFERING AT A PRICE TO PUBLIC OF $4.00 PER SHARE.  Full Article

Advaxis Announces Proposed Public Offering Of Common Stock
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Advaxis Inc ::ADVAXIS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ADVAXIS - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND ITS CONTINUED RESEARCH AND DEVELOPMENT INITIATIVES IN CONNECTION WITH ITS PRODUCT PIPELINE.  Full Article

Advaxis Reports Q1 EPS Of $0.18
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Advaxis Inc ::ADVAXIS REPORTS FIRST QUARTER FISCAL 2019 FINANCIAL RESULTS AND PROVIDES CLINICAL PIPELINE UPDATE.Q1 EARNINGS PER SHARE $0.18.Q1 REVENUE $15.6 MILLION.  Full Article

Advaxis’ Phase 3 Aim2cerv Study Placed On Partial Clinical Hold By FDA Related To Cmc Requests
Wednesday, 23 Jan 2019 

Advaxis Inc ::ADVAXIS’ PHASE 3 AIM2CERV STUDY PLACED ON PARTIAL CLINICAL HOLD BY FDA RELATED TO CMC REQUESTS.ADVAXIS INC - FDA DID NOT CITE ANY SAFETY ISSUES RELATED TO TRIAL AND ALL CURRENTLY ENROLLED PATIENTS WILL CONTINUE TO RECEIVE TREATMENT.ADVAXIS - NO NEW PATIENTS CAN ENROLL IN AIM2CERV UNTIL RESOLUTION OF FDA'S PARTIAL HOLD..ADVAXIS INC - HAVE ALREADY BEGUN EFFORTS TO ADDRESS FDA'S REQUESTS FOR INFORMATION.ADVAXIS - FDA'S RECENT COMMUNICATION STATES PARTIAL HOLD RELATED TO THEIR REQUESTS FOR ADDITIONAL INFORMATION PERTAINING TO CERTAIN AXAL CMC MATTERS.  Full Article

Advaxis - On Dec 10 Co Received Written Notice Of Termination From Amgen With Respect To License & Collaboration Agreement, Dated As Of Aug 1, 2016
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Advaxis Inc ::ADVAXIS - ON DEC 10 CO RECEIVED WRITTEN NOTICE OF TERMINATION FROM AMGEN WITH RESPECT TO LICENSE & COLLABORATION AGREEMENT, DATED AS OF AUG 1, 2016.ADVAXIS INC - TERMINATION OF AGREEMENT IS EFFECTIVE AS OF FEBRUARY 8, 2019 - SEC FILING.ADVAXIS INC - AGREEMENT IS PERTAINING TO DEVELOPMENT AND COMMERCIALIZATION OF CO'S ADXS-NEO PROGRAM.ADVAXIS - CO'S ADXS-NEO STUDY IS CURRENTLY ENROLLING PATIENTS AND CO WILL EVALUATE WHETHER TO RE-PARTNER ADXS-NEO PROGRAM.ADVAXIS -UPON TERMINATION, LICENSE TO AMGEN TO TERMINATE & CO TO REGAIN WORLDWIDE RIGHTS FOR DEVELOPMENT & COMMERCIALIZATION OF ADXS-NEO PROGRAM.  Full Article

Advaxis Reports Fiscal 2018 Q3 Loss Per Share Of $0.27
Monday, 10 Sep 2018 

Sept 10 (Reuters) - Advaxis Inc ::ADVAXIS REPORTS FISCAL 2018 THIRD QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.27.QTRLY REVENUE $1.2 MILLION VERSUS $3.1 MILLION.  Full Article

Advaxis Inc Files For Mixed Shelf Of Up To $250 Million
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Advaxis Inc ::ADVAXIS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION .  Full Article

Advaxis Announces FDA Allowance Of IND Application For ADXS-Hot Drug Candidate
Monday, 30 Jul 2018 

July 30 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES FDA ALLOWANCE OF IND APPLICATION FOR ADXS-HOT DRUG CANDIDATE FOR NON-SMALL CELL LUNG CANCER.ADVAXIS INC - AFFIRMS PLANS TO SUBMIT A TOTAL OF FOUR IND FOR DRUG CANDIDATES FROM ITS ADXS-HOT PROGRAM BY Q4 OF 2019.ADVAXIS - PLANS TO INITIATE PHASE 1/2 CLINICAL TRIAL THAT WILL SEEK TO ESTABLISH SAFETY, TOLERABILITY AND EFFECTIVENESS OF ADXS-503.ADVAXIS INC - ANTICIPATES FIRST PATIENT IN PHASE 1/2 TRIAL FOR THIS NSCLC DRUG CANDIDATE WILL BE DOSED BY END OF 2018.  Full Article

Advaxis Says FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac
Friday, 13 Jul 2018 

July 13 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES FDA LIFTS CLINICAL HOLD ON PHASE 1/2 COMBINATION STUDY OF AXALIMOGENE FILOLISBAC WITH DURVALUMAB.ADVAXIS INC - ENROLLMENT AND DOSING IN ALL OTHER ADVAXIS AND DURVALUMAB CLINICAL PROGRAMS WERE NOT AFFECTED BY CLINICAL HOLD.  Full Article

Advaxis Appoints Molly Henderson As Chief Financial Officer
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Advaxis Inc ::ADVAXIS APPOINTS MOLLY HENDERSON AS CHIEF FINANCIAL OFFICER.ADVAXIS INC - HENDERSON JOINS ADVAXIS FROM CEDAR CLIFF, LLC.  Full Article